Overview
AMLX market data
Price History
AMLX price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for AMLX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $24Benzinga · Jul 20, 2026, 11:34 AM
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $40Benzinga · Jun 25, 2026, 2:15 PM
Amylyx Pharma To Present Data From First-In-Human, Dose-Ranging Phase 1 LUMINA Trial Of AMX0114 At ENCALS Meeting 2026Benzinga · Jun 23, 2026, 11:15 AM
CORRECTION: Amylyx Pharmaceuticals Announced Results From Phase 2 Open-Label HELIOS Clinical Trial Of AMX0035 On May 15Benzinga · May 22, 2026, 12:05 PM
Amylyx Pharmaceuticals Publishes Data From Weeks 24, 48 Of Its Phase 2 HELIOS Study Of AMX0035 To Treat Wolfram Syndrome; Results Demonstrate Continued Improvements In Pancreatic Beta Cell Function Through Week 48Benzinga · May 15, 2026, 4:19 PM
8-K filing — Amylyx Pharmaceuticals, Inc. (AMLX)SEC EDGAR · May 7, 2026, 11:02 AM